SOAP Note Documentation for ER Follow-Up: Chronic Diarrhea with Hepatic Steatosis and Uncontrolled Diabetes
For a 67-year-old male with weeks-long diarrhea following cholecystectomy, test for bile acid diarrhea (BAD) first, as post-cholecystectomy patients have an 86% likelihood of positive testing, making this the most probable diagnosis 1.
SUBJECTIVE
Chief Complaint: ER follow-up for chronic diarrhea, nausea, and abdominal pain
History of Present Illness:
- Duration: Several weeks of symptoms causing work absences
- Symptoms: Diarrhea (specify frequency, consistency, presence of blood), nausea, abdominal pain (document location—right upper quadrant given history)
- ER findings: CT abdomen/pelvis showed hepatic steatosis; glucose 298 mg/dL
- Past surgical history: Cholecystectomy (critical risk factor for bile acid diarrhea)
Past Medical History:
- Hypertension
- Type 2 diabetes mellitus, uncontrolled (on insulin)
- Status post cholecystectomy
Current Medications:
- Insulin (specify type and dose)
- Antihypertensive (specify)
- Note: Ozempic previously denied by insurance—resubmitting
Review of Systems:
- Document weight changes, nocturnal diarrhea (suggests BAD or microscopic colitis), urgency, bloating
- Screen for symptoms of hypoglycemia given uncontrolled diabetes 2
OBJECTIVE
Vital Signs: BP, HR, weight (compare to previous), BMI
Physical Examination:
- General: Assess hydration status, nutritional state
- Abdomen: Tenderness (especially RUQ), hepatomegaly, surgical scars
- Skin: Assess for signs of chronic liver disease, insulin injection sites
Laboratory Data (from ER):
- Glucose: 298 mg/dL (significantly elevated)
- CT abdomen/pelvis: Hepatic steatosis (no mention of cirrhosis, masses, or other pathology)
ASSESSMENT
Chronic diarrhea, likely bile acid diarrhea (BAD) secondary to cholecystectomy (ICD-10: K91.1 - Postcholecystectomy syndrome)
- Post-cholecystectomy patients have 86% likelihood of positive SeHCAT testing for BAD 1
- Alternative diagnoses to exclude: microscopic colitis (less likely without nocturnal symptoms), celiac disease, chronic infection
Hepatic steatosis (ICD-10: K76.0 - Fatty liver, not elsewhere classified)
- Metabolic dysfunction-associated steatotic liver disease (MASLD) given concurrent type 2 diabetes 2
- Requires fibrosis risk stratification
Type 2 diabetes mellitus, uncontrolled (ICD-10: E11.65 - Type 2 diabetes with hyperglycemia)
Hypertension (ICD-10: I10 - Essential hypertension)
Nausea and abdominal pain (ICD-10: R11.0 - Nausea; R10.9 - Unspecified abdominal pain)
PLAN
1. Chronic Diarrhea Workup
Immediate Testing:
- H. pylori urea breath test (CPT: 83013) - as planned, though less likely causative for chronic diarrhea 4
- Stool studies:
Bile Acid Diarrhea Assessment:
- Empiric trial of bile acid sequestrant (cholestyramine 4g daily, titrate up) is most practical given 86% pre-test probability in post-cholecystectomy patients 1
- If SeHCAT testing available (not widely accessible in US): CPT 78299 (unlisted nuclear medicine procedure)
- Alternative: Serum 7α-hydroxy-4-cholesten-3-one if available 6
GI Referral: For persistent symptoms despite empiric BAD treatment or if alarm features develop
2. Hepatic Steatosis Management
Fibrosis Risk Stratification:
- Calculate FIB-4 index (age × AST / [platelet count × √ALT]) - first-line noninvasive tool 1
- Order comprehensive metabolic panel (CPT: 80053) including:
- AST, ALT, alkaline phosphatase, bilirubin, albumin
- Assess for hepatic synthetic function
- CBC with platelets (CPT: 85025) for FIB-4 calculation
- If FIB-4 suggests intermediate/high risk: Order transient elastography (FibroScan) (CPT: 91200) to quantify fibrosis 1
Additional Labs:
- Lipid panel (CPT: 80061) - dyslipidemia common with MASLD
- Hepatitis B and C screening (CPT: 87340,87520) to exclude viral causes
3. Diabetes Management
Immediate Labs:
- HbA1c (CPT: 83036) to assess long-term control 2
- Basic metabolic panel (CPT: 80048) - assess renal function given uncontrolled diabetes
- Urine microalbumin/creatinine ratio (CPT: 82043,82570) - screen for diabetic nephropathy
Medication Optimization:
- Continue insulin - adjust dose based on home glucose logs and HbA1c 7
- Resubmit prior authorization for semaglutide (Ozempic):
Diabetes Education:
- Hypoglycemia recognition and treatment 8
- Home glucose monitoring - check fasting and 2-hour postprandial
- Target glucose 80-130 mg/dL fasting, <180 mg/dL postprandial 2
4. Lifestyle Modifications
- Weight loss goal: >10% body weight through diet and exercise - improves both MASLD and diabetes 6
- Mediterranean diet - proven effective for hepatic steatosis regression 9
- Physical activity: 150 minutes/week moderate-intensity exercise 2
5. Follow-Up
- Return visit in 2-4 weeks (CPT: 99214 - established patient, moderate complexity) to review:
- Lab results and FIB-4 score
- Response to bile acid sequestrant
- Glucose logs and insulin adjustment
- Insurance authorization status for GLP-1 RA
- Gastroenterology referral if symptoms persist or FIB-4 indicates significant fibrosis risk
- Endocrinology referral if diabetes remains uncontrolled despite optimization
CPT CODES FOR TODAY'S VISIT
- 99214 - Office visit, established patient, 30-39 minutes, moderate complexity medical decision-making
ICD-10 CODES
- K91.1 - Postcholecystectomy syndrome (primary)
- E11.65 - Type 2 diabetes mellitus with hyperglycemia
- K76.0 - Fatty liver, not elsewhere classified
- I10 - Essential hypertension
- R19.7 - Diarrhea, unspecified
- R11.0 - Nausea
- R10.9 - Unspecified abdominal pain
Key Clinical Pearls
Post-cholecystectomy diarrhea has 86% likelihood of BAD - empiric bile acid sequestrant trial is reasonable before extensive testing 1. However, do not delay diabetes optimization - glucose of 298 mg/dL significantly increases risk of microvascular complications 2. The combination of hepatic steatosis and uncontrolled diabetes creates a vicious cycle; GLP-1 receptor agonists address both conditions simultaneously and should be aggressively pursued with insurance 3. Calculate FIB-4 immediately to risk-stratify liver disease, as cardiovascular events are the leading cause of death in MASLD patients 10.